Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.

Abstract

BACKGROUND The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP). METHODS Patients with CUP received carboplatin AUC 5 mg/mL a minute intravenously Day 1, gemcitabine 1000 mg/m(2) intravenously Days 1 and 8, and… (More)

Topics

3 Figures and Tables